You are here: Industry Insights > NICE

News List

NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis pharmatimes
November 09, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Rinvoq (upadacitinib) for people with previously treated severe active rheumatoid arthritis (RA).
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia europeanpharmaceuticalreview
November 06, 2020
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
Novo Nordisk’s Saxenda bags NICE recommendation pharmatimes
November 05, 2020
Novo Nordisk’s obesity management treatment Saxenda (liraglutide) has been recommended for use by the UK’s National Institute for Health and Care Excellence (NICE).
NICE recommends Novo Nordisk treatment for adults with obesity pharmaceutical-technology
November 02, 2020
National Institute for Health and Care Excellence (NICE) has recommended a new treatment option developed by Novo Nordisk for adults with obesity and non-diabetic hyperglycaemia.
NICE recommends testing womb cancer patients for inherited condition pharmatimes
October 30, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has released new guidance recommending that people with womb cancer should be tested for an inherited genetic condition.
Bayer’s Nubeqa wins NICE prostate cancer backing pharmatimes
October 29, 2020
Bayer’s Nubeqa has scored backing from the UK’s National Institute for Health and Care Excellence (NICE) for treating non-metastatic castration-resistant prostate cancer (nmCRPC).
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC europeanpharmaceuticalreview
October 26, 2020
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
ICR urges change as NICE rejects Keytruda plus chemotherapy pharmatimes
October 26, 2020
The Institute for Cancer Research (ICR) has called for change in the way immunotherapy drugs are researched and evaluated after the National Institute for Health and Care Excellence (NICE) handed MSD’s Keytruda plus chemotherapy a rejection.
Sanofi's Sarclisa bags NICE recommendation pharmatimes
October 19, 2020
French pharma Sanofi’s Sarclisa has been granted a positive recommendation from the National Institute for Health and Care (NICE) for patients with multiple myeloma.
NICE recommends Novartis’ Mayzent on the heels of SMC approval pharmatimes
October 16, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Mayzent for use by NHS England, only a few days after the Scottish Medicines Consortium (SMC) approved the multiple sclerosis (MS) drug.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page